influenza A virus

Overview

Influenza A virus (IAV) is an enveloped, negative-sense RNA virus in the family Orthomyxoviridae and is a major cause of seasonal influenza in humans and many animal species. It is biologically important because of its high mutation rate, antigenic variation, and capacity for reassortment, all of which contribute to recurrent epidemics, antiviral resistance, and occasional pandemics. The virus primarily infects the respiratory epithelium, which serves as the first immunological barrier and a key site of early host defense.

IAV is medically significant because it can cause illness ranging from uncomplicated upper respiratory infection to severe viral pneumonia, acute lung injury, and death, particularly in young children, older adults, pregnant individuals, and immunocompromised patients. Host responses involving pathways such as MAVS signaling, STAT1-associated inflammation, Toll-like receptor 7/8 signaling, and the TLR4/P2X7-NLRP3 axis have been studied in relation to disease severity and antiviral defense. Influenza A virus is also a major target for vaccination and antiviral drug development because of its broad public health burden and its ability to evade immunity through antigenic drift and subtype diversity.

Focus of Latest Publications

Recent publications examining influenza A virus have focused on advancing diagnostic and vaccine technologies alongside epidemiological characterization of disease severity. Diagnostic innovations have centered on rapid, multiplex detection systems employing CRISPR-based platforms coupled with recombinase polymerase amplification. Two independent studies developed one-pot systems capable of simultaneously detecting influenza A virus alongside other respiratory pathogens, achieving detection sensitivity of 8–10 copies per microliter within 30 minutes at a constant temperature of 40°C, with reported sensitivity and specificity exceeding 99.6% and 100% respectively, making these platforms suitable for point-of-care testing and field deployment.

Vaccine development has pursued multiple next-generation platforms designed to enhance protective immunity. Studies evaluated optimized mRNA-lipid nanoparticles, demonstrating that an H1N1 mRNA vaccine elicited robust antibody responses and full protection against lethal H1N1 challenge. A complementary approach developed adenoviral platforms enabling in vivo self-assembly of hemagglutinin-displaying virus-like particles; intranasal delivery of this Ad5-HA-VLP vaccine conferred long-lasting protection against both homologous and heterologous influenza A virus strains while driving robust mucosal secretory IgA and cytotoxic T lymphocyte responses. A separate study evaluated a dual-adjuvanted hemagglutinin stem nanoparticle vaccine in newborn primates, which induced broadly reactive stem-specific IgG antibodies with neutralizing activity, suggesting potential for universal vaccination in young infants. Additionally, a gene editing approach directing hematopoietic stem cells to produce long-term, high-level expression of broadly neutralizing anti-influenza antibodies conferred universal protection from heterologous lethal challenge in mice.

Clinical and epidemiological investigations revealed prognostic markers and population-level patterns of influenza A virus disease. Elevated transaminases were identified as a marker of increased disease severity in pediatric patients hospitalized with influenza. A large retrospective cohort of over 15,000 hospitalized influenza patients in Brazil found influenza A predominated (88.0%) and was associated with higher mortality than influenza B; independent protective factors included influenza vaccination and oseltamivir antiviral therapy. Molecular characterization studies in specific geographic regions identified circulating influenza A and B virus subtypes to inform local epidemic control strategies. Additionally, multiple analyses documented suboptimal influenza vaccination coverage in vulnerable populations, including children with cystic fibrosis and adult travelers, highlighting persistent gaps in preventive immunization strategies.